Combination of Metronomic Chemotherapy and Rituximab in Frail and Elderly Patients with Relapsed/Refractory Follicular Lymphoma and Ineligible for Lenalidomide Treatment: A Retrospective Analysis
Metronomic R-DEVEC-light is a feasible and effective disease-controlling strategy for frail, heavily pretreated rrFL patients who do not tolerate lenalidomide and are excluded from modern therapies. This schedule warrants further prospective evaluation and exploration in combination with targeted agents.
Authors
- Lucrezia De Marchi
- Marta Banchi (ORCID: https://orcid.org/0000-0003-0672-2066)
- Emanuele Cencini (ORCID: https://orcid.org/0000-0002-0432-9706)
- Andrea Nunzi (ORCID: https://orcid.org/0009-0001-3514-7980)
- Guido Bocci
- Claudia Seimonte
- Susanna Destefano
- Maria Christina Cox
- Alberto Fabbri
- Sabrina Pelliccia
Institutions
- University of Pisa (IT)
- University of Rome Tor Vergata (IT)
- Azienda Ospedaliera Sant'Andrea (IT)
- Azienda Ospedaliera Universitaria Senese (IT)
- Policlinico Tor Vergata (IT)
Publication Details
- Journal
- Cancers
- Published
- 2026-01-22
- DOI
- https://doi.org/10.3390/cancers18020347
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00